Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
Xeris Biopharma Holdings (Nasdaq: XERS) has appointed Dr. Anh Nguyen as Chief Medical Officer (CMO), succeeding Ken Johnson, who will retire on April 1, 2025. Dr. Nguyen, who previously worked at Xeris, will oversee the company's Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions.
Dr. Nguyen brings significant experience in developing first-in-class therapies and has previously served as Vice President at Asklepios Biopharmaceutical. His past achievements include contributing to the '21st Century Cures Act' and leading Gvoke®'s NDA and MAA approvals during his previous tenure at Xeris. The transition comes as Xeris prepares for Phase 3 development of XP-8121 and continues to grow its commercial portfolio, particularly Recorlev®.
Xeris Biopharma Holdings (Nasdaq: XERS) ha nominato il Dr. Anh Nguyen come Chief Medical Officer (CMO), succedendo a Ken Johnson, che andrà in pensione il 1 aprile 2025. Il Dr. Nguyen, che ha precedentemente lavorato in Xeris, supervisionerà le funzioni Mediche, Regolatorie, Precliniche e di Sviluppo Clinico, oltre alla Farmacovigilanza dell'azienda.
Il Dr. Nguyen porta con sé una significativa esperienza nello sviluppo di terapie innovative e ha precedentemente ricoperto il ruolo di Vice Presidente presso Asklepios Biopharmaceutical. Tra i suoi successi passati ci sono contributi al '21st Century Cures Act' e la guida delle approvazioni NDA e MAA di Gvoke® durante la sua precedente permanenza in Xeris. Questa transizione avviene mentre Xeris si prepara per lo sviluppo di Fase 3 di XP-8121 e continua ad espandere il proprio portafoglio commerciale, in particolare Recorlev®.
Xeris Biopharma Holdings (Nasdaq: XERS) ha nombrado al Dr. Anh Nguyen como Director Médico (CMO), sucediendo a Ken Johnson, quien se retirará el 1 de abril de 2025. El Dr. Nguyen, que anteriormente trabajó en Xeris, supervisará las funciones Médicas, Regulatorias, Preclínicas y de Desarrollo Clínico, así como la Farmacovigilancia de la empresa.
El Dr. Nguyen aporta una experiencia significativa en el desarrollo de terapias de primera clase y ha ocupado anteriormente el cargo de Vicepresidente en Asklepios Biopharmaceutical. Sus logros anteriores incluyen contribuciones a la 'Ley de Curaciones del Siglo XXI' y liderar las aprobaciones NDA y MAA de Gvoke® durante su anterior mandato en Xeris. La transición se produce mientras Xeris se prepara para el desarrollo de Fase 3 de XP-8121 y continúa expandiendo su cartera comercial, especialmente Recorlev®.
Xeris Biopharma Holdings (Nasdaq: XERS)는 Dr. Anh Nguyen을 최고 의학 책임자(CMO)로 임명하였으며, 그는 2025년 4월 1일 은퇴하는 Ken Johnson을 대신하게 됩니다. 이전에 Xeris에서 근무했던 Nguyen 박사는 회사의 의학, 규제, 전임상 및 임상 개발, 그리고 약물 감시 기능을 감독할 것입니다.
Nguyen 박사는 혁신적인 치료법 개발에 대한 상당한 경험을 가지고 있으며, 이전에 Asklepios Biopharmaceutical의 부사장으로 재직했습니다. 그의 과거 성과에는 '21세기 치료법 법안'에 대한 기여와 Xeris에서 근무하던 중 Gvoke®의 NDA 및 MAA 승인 주도가 포함됩니다. 이 전환은 Xeris가 XP-8121의 3상 개발을 준비하고, 특히 Recorlev®를 중심으로 상업 포트폴리오를 확장하는 가운데 이루어집니다.
Xeris Biopharma Holdings (Nasdaq: XERS) a nommé Dr. Anh Nguyen au poste de Directeur Médical (CMO), succédant à Ken Johnson, qui prendra sa retraite le 1er avril 2025. Dr. Nguyen, qui a précédemment travaillé chez Xeris, supervisera les fonctions Médicales, Réglementaires, Précliniques et de Développement Clinique, ainsi que la Pharmacovigilance de l'entreprise.
Dr. Nguyen apporte une expérience significative dans le développement de thérapies de première classe et a précédemment occupé le poste de Vice-Président chez Asklepios Biopharmaceutical. Ses réalisations passées incluent des contributions à la 'Loi sur les Cures du 21ème Siècle' et la direction des approbations NDA et MAA de Gvoke® lors de son précédent mandat chez Xeris. Cette transition se produit alors que Xeris se prépare pour le développement de la Phase 3 de XP-8121 et continue d'élargir son portefeuille commercial, en particulier Recorlev®.
Xeris Biopharma Holdings (Nasdaq: XERS) hat Dr. Anh Nguyen zum Chief Medical Officer (CMO) ernannt, der Ken Johnson nachfolgt, der am 1. April 2025 in den Ruhestand geht. Dr. Nguyen, der zuvor bei Xeris tätig war, wird die medizinischen, regulatorischen, präklinischen und klinischen Entwicklungs- sowie Pharmakovigilanzfunktionen des Unternehmens leiten.
Dr. Nguyen bringt umfangreiche Erfahrung in der Entwicklung von Therapien der ersten Klasse mit und war zuvor Vizepräsident bei Asklepios Biopharmaceutical. Zu seinen bisherigen Erfolgen gehört die Mitwirkung am '21st Century Cures Act' sowie die Leitung der NDA- und MAA-Zulassungen von Gvoke® während seiner früheren Tätigkeit bei Xeris. Der Übergang erfolgt, während Xeris sich auf die Entwicklung der Phase 3 von XP-8121 vorbereitet und weiterhin sein kommerzielles Portfolio, insbesondere Recorlev®, ausbaut.
- Smooth leadership transition planned with retiring CMO staying until April 2025
- New CMO has previous successful experience with the company, including Gvoke® approvals
- Strategic timing with upcoming Phase 3 development of XP-8121
- None.
Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire
“We are pleased to have Anh return to Xeris as our first Chief Medical Officer. Anh is an accomplished clinician-scientist and biopharma executive dedicated to driving advancements in regulatory strategy, clinical development, medical affairs, and commercial launches,” said John Shannon, CEO of Xeris. “He brings his forward-thinking leadership to Xeris at a time when we prepare to embark in our Phase 3 development of XP-8121 and continue to drive growth of our commercial portfolio, especially Recorlev®.”
Mr. Shannon continued, “We are fortunate that Ken has strategically played an active role in finding his successor and has graciously agreed to help and support in the transition of his organization under the new leadership of Anh. Ken’s guidance and support will undoubtedly ensure a smooth passing of the baton and set the stage for continued success of the entire Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions.”
Dr. Nguyen brings an extensive wealth of clinical and leadership experience to his role as CMO, leading the development of first-in-class therapies including circular RNA-based oncology treatments, gene-edited xenotransplants, immuno-oncology vaccines, and allogeneic CAR-T therapies. Dr. Nguyen served as Vice President and Therapeutic Sector Lead at Asklepios Biopharmaceutical (AskBio), where he directed the IND clearance and early-phase clinical trials of AAV gene therapies for neuromuscular rare disease. Among his many achievements, Dr. Nguyen shaped clinical and regulatory policies for breakthrough therapies while serving as a medical officer at the NIH, FDA, and CMS. During his Robert Wood Johnson Foundation Health Policy Fellowship serving on the US Senate HELP Committee, Dr. Nguyen was a key contributor to the landmark "21st Century Cures Act". He also led the establishment of an ambulatory surgical service to expedite pediatric orphan disease and oncology trials, earning the prestigious NIH Director's Award. During his tenure at Xeris, Dr. Nguyen served as the program medical lead for Gvoke®’s NDA and MAA approvals and multiple IND clearances for endocrine and rare disease, including novel endocrine drug co-formulations for diabetes, immunology, and pediatric epilepsy. Dr. Nguyen received an MBA from University of
“It has been an honor to be part of an exceptionally talented team and a privilege to help lead Xeris through its evolution to a commercial-stage biopharmaceutical company,” said Ken Johnson. “I’m very proud of what we have accomplished and am confident that Dr. Nguyen will lead Xeris to new levels of success.”
“I’m excited to help lead the scientific efforts at Xeris, to collaborate and usher a new era of transformative therapies that leverage our innovation and strategic partnerships, to redefine patient care,” said Dr. Nguyen.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in
Forward-Looking Statements
Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including the development of its product portfolio vision and strategy for its internal functions, the potential growth of its commercial portfolio, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators’ ability to protect its intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings with the Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224024050/en/
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
When will Dr. Anh Nguyen take over as Xeris (XERS) Chief Medical Officer?
What are Dr. Anh Nguyen's key achievements before joining Xeris (XERS) as CMO?
What products will Dr. Nguyen oversee in his role as Xeris (XERS) CMO?
What was Dr. Nguyen's previous involvement with Xeris (XERS)?
